Clinical trials of the drug for coronavirus “Areplivir” will be published in full. This became known from the chairman of the board of directors of the manufacturing company “Promomed” Petr Bely, RIA Novosti quoted him as saying.
He noted that studies on the tablet form of this drug were published in the international registry of clinical trials ClinicalTrials.gov , which is the main resource for clinical trials.
The Ministry of Health authorized the temporary registration of an injectable drug based on partial data.
“A full report will be provided shortly, it will be submitted to the Ministry of Health. And if the Ministry of Health approves it, we will certainly give it to international experts for licensing and, of course, we will make the results public, ”Bely said.
Earlier it was reported that Areplivir would enter hospitals. A multicenter clinical trial of the drug led by Academician of the Russian Academy of Sciences Dmitry Pushkar confirmed the efficacy and safety of the drug.
Areplivir has also been developed for oral administration; hospitals. The final decision will be made by the Russian Ministry of Health when revising guidelines on coronavirus.